Minimally invasive surgery is feasible after preoperative chemotherapy for stage IV gastric cancer. Issue 4 (29th May 2020)

• Record Type: Journal Article
• Authors: Yamamoto, Kazuyoshi; Omori, Takeshi; Hara, Hisashi; Shinno, Naoki; Sugimura, Keijiro; Miyata, Hiroshi; Takahashi, Hidenori; Fujiwara, Yoshiyuki; Ohue, Masayuki; Yano, Masahiko
• Is Part Of: Annals of gastroenterological surgery. Volume 4:Issue 4(2020)
• Page Start: 396
• Page End: 404
• Publication Date: 2020-05-29
• Subjects: conversion surgery -- gastric cancer -- laparoscopic -- minimally invasive surgery -- robotic; Digestive organs -- Surgery -- Periodicals; 617.43
• DOI: 10.1002/ags3.12343
• Languages: English
• ISSNs: 2475-0328

Abstract

Abstract: Aim: To elucidate the safety and feasibility of minimally invasive surgery (MIS) as conversion surgery after chemotherapy for stage IV gastric cancer, we compared the background characteristics and clinical courses of patients who underwent open conversion surgery (open group) versus MIS (MIS group). Methods: We included 94 consecutive patients with stage IV gastric cancer who received chemotherapy followed by conversion surgery gastric resection from January 2011 to October 2019 at the Osaka International Cancer Institute in this analysis. Results: The open group included more patients who had macroscopic peritoneal metastasis and required splenectomy. However, other background characteristics, including preoperative chemotherapy duration, were comparable. The MIS group had significantly longer operative time (266 vs 339 minutes, P = .0039) and less operative blood loss (520 vs 10 mL, P < .0001). The incidence of postoperative complication of Clavien‐Dindo grade II or higher was non‐significantly lower (24.5% vs 9.8%, P = .058) and length of postoperative hospital stay was significantly shorter in the MIS group (12 vs 8 days, P < .0001). Even though the open group included more patients with more advanced (ypT4a or higher, or N3) disease, the MIS group had better recurrence free survival and overall survival (OS). Multivariate analysis revealed that N status (hazard ratio [HR], 4.39; 95% confidence interval [CI], 2.18‐12.26; P < .0001) and T status (2.11; 1.05‐4.36; P = .036) were independent prognostic factors for OS. MIS was not a negative prognostic factor for OS (HR, 0.44; 95% CI, 0.15‐1.10; P = .081). Conclusion: MIS can be safely performed as conversion surgery following chemotherapy for stage IV gastric cancer. Abstract :